Japanese Pharma Astellas Licenses MorphoSys' HuCAL Library | GenomeWeb
NEW YORK (GenomeWeb News) — Astellas Pharma will use MorphoSys’ HuCAL Gold antibody library in its drug-discovery efforts, MorphoSys said today.
 
Under the agreement, MorphoSys will receive an up-front payment and user fees over the course of the license, which may last up to five years.
 
MorphoSys said it could also receive research funding from preclinical and clinical development of compounds, as well as licensing, milestone, and royalty payments. 
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.